

## Supporting Information

*Rec. Nat. Prod.* 11:6 (2017) 514-520


### **Prenylated Flavonoids from *Epimedium koreanum* Nakai and their Human Neutrophil Elastase Inhibitory Effects**

**Soo Min Lee, Yeong Hun Song, Zia Uddin, Yeong Jun Ban and  
Ki Hun Park\***


*Division of Applied Life Science (BK21 plus), IALS, Graduate School of Gyeongsang  
National University, Jinju 660-701, Republic of Korea*

<b>Table of Contents</b>	<b>Page</b>
<b>S1:</b> <sup>1</sup> H-NMR (500 MHz) and <sup>13</sup> C-NMR (125 MHz) spectrum of compound <b>1</b> (MeOD).	2
<b>S2:</b> HMBC spectrum of compound <b>1</b> .	3
<b>S3:</b> HREIMS data of compound <b>1</b> .	4
<b>S4:</b> <sup>1</sup> H-NMR (500 MHz) and <sup>13</sup> C-NMR (125 MHz) spectrum of compound <b>2</b> (MeOD).	5
<b>S5:</b> HMBC spectrum of compound <b>2</b> .	6
<b>S6:</b> HREIMS data of compound <b>2</b> .	7
<b>S7:</b> <sup>1</sup> H-NMR (500 MHz) and <sup>13</sup> C-NMR (125 MHz) spectrum of compound <b>3</b> (MeOD).	8
<b>S8:</b> HMBC spectrum of compound <b>3</b> .	9
<b>S9:</b> HREIMS data of compound <b>3</b> .	10
<b>S10:</b> <sup>1</sup> H-NMR (500 MHz) and <sup>13</sup> C-NMR (125 MHz) spectrum of compound <b>4</b> (MeOD).	11
<b>S11:</b> HMBC spectrum of compound <b>4</b> .	12
<b>S12:</b> HRFABMS data of compound <b>4</b> .	13
<b>S13:</b> Kinetic data for the inhibition of human neutrophil elastase by compound <b>1-4</b>	14
<b>S14:</b> Kinetic data for the inhibition of human neutrophil elastase by compound <b>2</b>	15
<b>S15:</b> Plant Material	16

# <sup>1</sup>H NMR




# <sup>13</sup>C NMR




S1: <sup>1</sup>H-NMR (500 MHz) and <sup>13</sup>C-NMR (125 MHz) spectrum of compound 1 (MeOD).

# HMBC



S2: HMBC spectrum of compound 1.




Data : 45-b1-HR Date : 11-Jul-2016 17:22  
 Instrument : MStation  
 Sample : -  
 Note : -  
 Inlet : Direct Ion Mode : EI+  
 RT : 0.84 min Scan# : 26  
 Elements : C 100/1, H 100/1, O 10/1  
 Mass Tolerance : 1000ppm, 3mmu if m/z > 3  
 Unsaturation (U.S.) : -0.5 - 20.0

Observed m/z	Int%	Err [ppm / mmu]	U.S. Composition
1 422.1727	54.93	-0.6 / -0.2	13.0 C <sub>25</sub> H <sub>26</sub> O <sub>6</sub>


### S3: HREIMS data of compound 1.

*Epimedokoreanin B (1)*: pale yellow powder; EIMS,  $m/z$  422  $[M]^+$ ; HREIMS,  $m/z$  422.1727 (calcd for C<sub>25</sub>H<sub>26</sub>O<sub>6</sub>); <sup>1</sup>H-NMR (MeOD, 500 MHz)  $\delta_H$  6.36 (1H, s), 6.13 (1H, s), 7.13 (1H, d,  $J = 2.1$  Hz), 7.21 (1H, d,  $J = 2.2$  Hz), 3.25 (2H, d,  $J = 7.3$  Hz), 5.18 (1H, m), 1.66 (3H, d,  $J = 0.9$  Hz), 1.57 (3H, d,  $J = 0.8$  Hz), 3.40 (2H, d,  $J = 7.1$  Hz), 5.24 (1H, dddd,  $J = 7.4, 6.0, 2.8, 1.4$  Hz), 1.69 (3H, s), 1.64 (3H, s). <sup>13</sup>C-NMR (MeOD, 500 MHz)  $\delta_C$  165.08, 101.80, 182.79, 159.33, 99.14, 161.97, 106.81, 154.96, 103.79, 121.50, 110.12, 145.06, 147.61, 128.75, 118.99, 27.65, 121.80, 132.55, 24.60, 16.49, 21.23, 122.13, 131.28, 24.52, 16.19.

# <sup>1</sup>H NMR




# <sup>13</sup>C NMR




**S4:** <sup>1</sup>H-NMR (500 MHz) and <sup>13</sup>C-NMR (125 MHz) spectrum of compound **2** (MeOD).

# HMBC



S5: HMBC spectrum of compound 2.




Data : 37\_26\_1\_HR Date : 16-Aug-2016 18:06  
 Instrument : MStation  
 Sample : -  
 Note : -  
 Inlet : Direct Ion Mode : EI+  
 RT : 0.87 min Scan# : 27  
 Elements : C 100/1, H 100/1, O 10/1  
 Mass Tolerance : 1000ppm, 3mmu if m/z > 3  
 Unsaturation (U.S.) : -0.5 - 20.0

Observed m/z	Int%	Err [ppm / mmu]	U.S. Composition
1 406.1776	100.00	-1.0 / -0.4	13.0 C25 H26 O5


**S6: HREIMS data of compound 2.**

5, 7, 4'-trihydroxy-8, 3'-diprenylflavone (**2**): white powder; EIMS,  $m/z$  406  $[M]^+$ ; HREIMS,  $m/z$  406.1776 (calcd for  $C_{25}H_{26}O_5$ );  $^1H$ -NMR (MeOD, 500 MHz)  $\delta_H$  6.34 (1H, s), 6.10 (1H, s), 7.48 (1H, d,  $J = 6.5$  Hz), 6.74 (1H, d,  $J = 8.3$  Hz), 7.55 (1H, d,  $J = 2.1$  Hz), 3.22 (2H, s), 5.22 (1H, t,  $J = 7.4$  Hz), 1.68 (3H, s), 1.62 (3H, s), 3.34 (2H, d,  $J = 6.9$  Hz), 5.13 (1H, t,  $J = 6.9$  Hz), 1.66 (3H, s), 1.56 (3H, s).  $^{13}C$ -NMR (MeOD, 500 MHz)  $\delta_C$  164.79, 101.70, 182.71, 159.30, 98.13, 161.88, 106.71, 154.91, 103.81, 128.83, 127.28, 114.76, 159.04, 132.73, 125.41, 29.28, 121.66, 121.81, 16.51, 21.25, 24.54, 122.33, 131.12, 16.82, 27.66.

# <sup>1</sup>H NMR





# <sup>13</sup>C NMR




**S7:** <sup>1</sup>H-NMR (500 MHz) and <sup>13</sup>C-NMR (125 MHz) spectrum of compound 3 (MeOD).



# HMBC



S8: HMBC spectrum of compound 3.




Data : 45-b1-HR Date : 11-Jul-2016 17:22  
 Instrument : MStation  
 Sample : -  
 Note : -  
 Inlet : Direct Ion Mode : EI+  
 RT : 0.84 min Scan# : 26  
 Elements : C 100/1, H 100/1, O 10/1  
 Mass Tolerance : 1000ppm, 3mmu if m/z > 3  
 Unsaturation (U.S.) : -0.5 - 20.0

	Observed m/z	Int%	Err [ppm / mmu]	U. S. Composition
1	422.1727	54.93	-0.6 / -0.2	13.0 C25 H26 O6


### S9: HREIMS data of compound 3.

*Neophellamuretin (3)*: yellow powder; EIMS,  $m/z$  356  $[M]^+$ ; HREIMS,  $m/z$  356.1260 (calcd for  $C_{20}H_{20}O_6$ );  $^1H$ -NMR (MeOD, 500 MHz)  $\delta_H$  4.82 (1H, s), 4.39 (1H, s), 8.87 (1H, s), 7.26 (2H, d,  $J = 8.5$  Hz), 6.74 (2H, d,  $J = 8.6$  Hz), 3.03 (2H, s), 5.01 (1H, s), 1.50 (3H, s), 1.40 (3H, s).  $^{13}C$ -NMR (MeOD, 500 MHz)  $\delta_C$  83.43, 72.31, 197.36, 161.57, 95.33, 165.01, 107.85, 159.85, 100.44, 128.16, 128.93, 114.70, 157.71, 20.91, 122.27, 130.33, 24.57, 16.46.

# <sup>1</sup>H NMR




# <sup>13</sup>C NMR




**S10:** <sup>1</sup>H-NMR (500 MHz) and <sup>13</sup>C-NMR (125 MHz) spectrum of compound 4 (MeOD).

# HMBC



S11: HMBC spectrum of compound 4.




[ Elemental Composition ]

Data : 65-b2-HR Date : 11-Oct-2016 15:14  
 Sample: -  
 Note : -  
 Inlet : Direct Ion Mode : FAB+  
 RT : 1.92 min Scan#: 24  
 Elements : C 100/1, H 150/1, O 10/1  
 Mass Tolerance : 100ppm, 3mmu if m/z > 30  
 Unsaturation (U.S.) : 0.0 - 20.0


Observed m/z	Int%	Err[ppm / mmu]	U.S.	Composition
369.1329	100.0	-2.4 / -0.9	11.5	C 21 H 21 O 6

**S12:** HRFABMS data of compound **4**.

*Icariside II* (**4**): pale yellow powder; EIMS,  $m/z$  369  $[M]^+$ ; HRFABMS,  $m/z$  369.1329 (calcd for  $C_{21}H_{21}O_6$ );  $^1H$ -NMR (MeOD, 500 MHz)  $\delta_H$  6.16 (1H, s), 7.76 (2H, d,  $J = 9.0$  Hz), 6.99 (2H, d,  $J = 9.0$  Hz), 3.79 (3H, s), 3.34 (2H, dd,  $J = 20.5, 6.8$  Hz), 4.13 (1H, d,  $J = 1.6$  Hz), 1.61 (3H, s), 1.56 (3H, s), 5.30 (1H, d,  $J = 1.5$  Hz), 3.61 (1H, dd,  $J = 9.2, 3.3$  Hz), 3.25 (2H, s), 3.25 (2H, s), 3.18 (1H, d,  $J = 6.0$  Hz), 0.80 (3H, d,  $J = 6.0$  Hz).  $^{13}C$ -NMR (MeOD, 500 MHz)  $\delta_C$  157.35, 134.84, 178.47, 159.40, 102.07, 161.83, 106.52, 154.37, 104.60, 122.73, 130.40, 113.75, 161.98, 54.60, 21.04, 122.29, 131.07, 16.75, 24.50, 97.97, 70.71, 70.51, 78.06, 71.78, 16.27.



**S13:** Lineweaver-Burk plot for the inhibition of human neutrophil elastase by compound **1-4** (left). Dixon plots for the inhibition of compound **1-4** (right).



**S14:** (A) Lineweaver-Burk plots were constructed for the inhibition of HNE by compound **2**. Insets (I) and (II) represent secondary plots of slope and intercept of the straight lines versus concentration of compound **2**, respectively. (B) Dixon plots for the inhibition of compound **2** on HNE activity.

[Plant Material]



**S15: Plant Material**

*Epimedium koreanum* NAKAI. (三枝九葉草, 淫羊藿) (삼지구엽초, 음양곽)

**Manufacturer : Handsherb Co.,Ltd, Republic of Korea**

752, Cheonmun-ro, Yeongcheon-si, Gyeongsangbuk-do, Republic of Korea